New Enterprise Associates, Inc. (NEA) has a strong track record of investing in innovative companies that are transforming the healthcare industry. NEA has nearly $17 billion in committed capital and is currently investing $2.8 billion from their 15th Fund (NEA 15). Can you be their next investment?
NEA, a global venture capital firm focused on helping entrepreneurs building transformational businesses across multiple sectors and stages, is visiting Johnson & Johnson Innovation, JLABS (JLABS) on September 20, 2016. NEA invests in life science innovators with biopharma focus areas including clinical drug development and drug discovery.
Since 1977, NEA has partnered with technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions.
Frank Torti, M.D., Partner at NEA, will be in attendance to give an overview presentation covering key areas of interest and best practices when seeking startup funds. Following the presentation, don't miss the opportunity to introduce yourself to Frank during the networking lunch. Finally, for those companies who apply online and are approved, one-on-one meetings with NEA will provide a brief forum to further discuss your company.
NEA's healthcare investing has a focus biopharmaceuticals, healthcare services/IT and medical devices. Leaders from the life science industry are encouraged to apply to meet with NEA!
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and been approved. The application period ended on August 15th.
New Enterprise Associates, Inc. (NEA) is a leading venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $17 billion in committed capital, NEA invests in information technology, healthcare and energy technology companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions. For additional information, www.nea.com.
NEA Participating Representative:
Frank Torti, M.D. | Partner, New Enterprise Associates, Inc.
Frank Torti joined NEA in 2007 and focuses on investments in biopharmaceuticals, medical devices, and healthcare services. He has been actively involved in the firm's private and public investments in healthcare, including Alimera Sciences, Cadence Pharmaceuticals (acquired by Mallinckrodt plc), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), Dermira, Galera Therapeutics, Neotract, Novast Pharmaceuticals, Peplin (acquired by LEO Pharma), Rigel, Solta Medical (acquired by Valeant) and Tarveda Therapeutics. Prior to joining NEA, Frank worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Frank's experience also includes public market investing at the Wasatch Advisors mutual fund family and business development work with the consumer-directed healthcare startup Revolution Health Group. Frank received his medical degree from the University of North Carolina School of Medicine, his MBA with distinction from Harvard Business School, and his BA with highest honors from the University of North Carolina, where he was a Morehead Scholar.
Connect with Frank:
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on September 19th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on August 15th. Your application will be reviewed and you will be notified of acceptance on September 8th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
When & Where
JLABS Bay Area
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.